On September 6, 2016 GlycoMimetics, Inc. (NASDAQ: GLYC) reported dosing of the first healthy volunteers in a new Phase 1 clinical trial evaluating its novel combined E-selectin and CXCR4 antagonist GMI-1359 (Press release, GlycoMimetics, SEP 6, 2016, View Source [SID:1234514958]). In this first-in-humans trial, volunteer participants will receive a single injection of GMI-1359, which will be evaluated for safety, tolerability, pharmacokinetics and pharmacodynamics. GlycoMimetics intends to develop GMI-1359 as a potential treatment for hematologic malignancies. Schedule your 30 min Free 1stOncology Demo! "Our preclinical data points to the potential of GMI-1359 to inhibit the growth and metastasis of a variety of cancers. We believe this is due to a novel mechanism of action provided by inhibiting both E-selectin and CXCR4 simultaneously," said Helen Thackray, M.D., Chief Medical Officer of GlycoMimetics. "This first clinical trial will position the program for further development in hematologic malignancies and other cancers."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The randomized, double-blind escalating dose study is being conducted at a single site in the United States. Each volunteer will receive a single dose of GMI-1359, and participate for 16 days of evaluation during the trial.
Previous preclinical research has been shared via oral and poster presentations at the annual meetings of both the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual and the American Society of Hematology (ASH) (Free ASH Whitepaper). Data presented have demonstrated activity in models of acute myelogenous leukemia (AML), prostate cancer and pancreatic cancer.